Therapeutic uses of aromatase inhibitors in men

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 3, 2007, Pages 235-240

  De Ronde, Willem ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aromatase; Estradiol; Men

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ATAMESTANE; BICALUTAMIDE; CLOMIFENE; EXEMESTANE; FOLLITROPIN; FORMESTANE; LETROZOLE; LUTEINIZING HORMONE; PLACEBO; TAMOXIFEN; TESTOLACTONE; TESTOSTERONE;

ANDROGEN DEFICIENCY; BODY HEIGHT; BONE METABOLISM; CLINICAL TRIAL; DELAYED PUBERTY; DRUG EFFECT; ENZYME INHIBITION; EPIPHYSIS; ESTROGEN METABOLISM; GYNECOMASTIA; HUMAN; HYPOGONADISM; MALE BREAST; OBESITY; PHENOTYPE; PRECOCIOUS PUBERTY; REVIEW; SHORT STATURE; SPERMATOGENESIS; TESTOSTERONE BLOOD LEVEL;

AROMATASE INHIBITORS; ESTROGEN ANTAGONISTS; ESTROGENS; HUMANS; LUTEINIZING HORMONE; MALE; PHENOTYPE; TESTOSTERONE;

EID: 34247610971     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328121aad2     Document Type: Review

References (60)

1. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337:91-95.
2. Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89:61-70.
3. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689-3698.
4. Herrmann BL, Saller B, Janssen OE, et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 2002; 87:5476-5484.
5. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-3635.
6. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126-5137.
7. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 2001; 142:4589-4594.
8. Stoffel-Wagner B, Watzka M, Schramm J, et al. Expression of CYP19 (aromatase) mRNA in different areas of the human brain. J Steroid Biochem Mol Biol 1999; 70:237-241.
9. Schindler AE, Ebert A, Friedrich E. Conversion of androstenedione to estrone by human tissue. J Clin Endocrinol Metab 1972; 35:627-630.
10. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab 1994; 78:428-432.
11. Longcope C, Pratt JH, Schneider SH, Fineberg SE. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 1978; 46:146-152.
12. Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by isolated human hairs. J Clin Endocrinol Metab 1975; 40:413-417.
13. Schweikert HU, Wolf L, Romalo G. Oestrogen formation from androstenedione in human bone. Clin Endocrinol (Oxf) 1995; 43:37-42.
14. Harada N, Sasano H, Murakami H, et al. Localized expression of aromatase in human vascular tissues. Circ Res 1999; 84:1285-1291.
15. Baird DT, Horton R, Longcope C, Tait JF. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969; 25:611-664.
16. MacDonald PC, Madden JD, Brenner PF, et al. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49:905-916.
17. de Ronde W, Hofman A, Pols HA, de Jong FH. A direct approach to the estimation of the origin of oestrogens and androgens in elderly men by comparison with hormone levels in postmenopausal women. Eur J Endocrinol 2005; 152:261-268.
18. de Ronde W, van der Schouw YT, Muller M, et al. Associations of sex-hormone-binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. J Clin Endocrinol Metab 2005; 90:157-162.
19. Bouillon R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 2004; 89:6025-6029.
20. Deladoey J, Fluck C, Bex M, et al. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 1999; 84:4050-4054.
21. Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998; 83:1348-1357.
22. Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348:1855-1865.
23. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
24. Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006; 91:3324-3328.
25. T'sjoen GG, Giagulli VA, Delva H, et al. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 2005; 90:5717-5722.
26. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106:1553-1560.
27. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20:751-757.
28. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26:833-876.
29. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91:1995-2010.
30. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28:125-127.
31. Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004; 89:1174-1180.
32. Muller M, van den Beld AW, van der Schouw YT, et al. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J Clin Endocrinol Metab 2006; 91:3988-3991.
33. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.
34. Kley HK, Deselaers T, Peerenboom H, Kruskemper HL. Enhanced conversion of androstenedione to estrogens in obese males. J Clin Endocrinol Metab 1980; 51:1128-1132.
35. Strain GW, Zumoff B, Miller LK, et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 1988; 66:1019-1023.
36. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 2005; 7:211-215.
37. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003; 52:1126-1128.
38. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996; 81:1821-1826.
39. Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; 2:CD000151.
40. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001; 165:837-841.
41. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167:624-629.
42. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989; 10:240-247.
43. Laue L, Jones J, Barnes KM, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993; 76:151-155.
44. Lefevre H, Bouvattier C, Lahlou N, et al. Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol 2006; 154:221-227.
45. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:6396-6402.
46. Wickman S, Sipila I, Ankarberg-Lindgren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357:1743-1748.
47. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006; 64:510-513.
48. Van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 45:2900-2906.
49. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4428-4433.
50. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000; 133:951-963.
51. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86:192-199.
52. Khosla S, Melton LJ III, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83:2266-2274.
53. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86:3555-3561.
54. Gennari L, Merlotti D, Martini G, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88:5327-5333.
55. Khosla S, Melton LJ III, Robb RA, et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005; 20:730-740.
56. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982; 16:801-810.
57. Szulc P, Claustrat B, Munoz F, et al. Assessment of the role of 17beta-oestradiol in bone metabolism in men: does the assay technique matter? The MINOS study. Clin Endocrinol (Oxf) 2004; 61:447-457.
58. Leder BZ, LeBlanc KM, Schoenfeld DA, et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88:204-210.
59. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int 2005; 16:1487-1494.
60. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003; 88:3785-3793.